Previous 10 | Next 10 |
InMed Pharmaceuticals (NASDAQ: INM) President and CEO Eric A. Adams recently hosted a conference call and webcast in which he emphasized the company’s successful product diversification and strategic acquisition achievements. He expressed his optimism at the company’s expansi...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 202...
InMed Pharmaceuticals (NASDAQ:INM) announced that CFO Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the company effective Mar.31, 2022. Mr. Colwill will continue to serve as an advisor through June 30, 2022 to facilitate a smooth transition....
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces that its Chie...
InMed Pharmaceuticals (NASDAQ: INM) , a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditio...
The following slide deck was published by InMed Pharmaceuticals Inc. in conjunction with this event. For further details see: InMed Pharmaceuticals (INM) Investor Presentation - Slideshow
InMed Pharmaceuticals (NASDAQ: INM) is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer mar...
In a recent update, InMed Pharmaceuticals president and CEO, Eric A. Adams, lauded the company’s progress and achievements so far, particularly with its product diversification and strategic acquisitions Adams noted the company’s commitment to launching more products...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that its president and CEO Eric A. Adams will be presenting at the 34th Annual Roth Conference being held March 13-15, 2022. Adams will ho...
Vancouver, BC, March 08, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces that Er...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...